Publication Type : Journal Article
Publisher : Drug Development Research
Source : Drug Development Research, Volume 72, Number 8, p.772-778 (2011)
Keywords : angiogenesis, Arthritis, autoimmune disease, Buerger disease, chronic kidney disease, cyclic AMP, cyclic GMP, fibrosing alveolitis, immune function test, immunoglobulin A nephropathy, immunomodulation, multiple sclerosis, nonhuman, pentoxifylline, Peyronie disease, phosphodiesterase, phosphodiesterase inhibitor, proliferative glomerulonephritis, pulmonary hypertension, Raynaud phenomenon, regulatory T lymphocyte, renal protection, review, rheumatoid arthritis, rolipram, scleroderma, sildenafil, systemic sclerosis, tadalafil, unclassified drug, uveitis, vardenafil, ym 393059
Campus : Kochi
School : School of Medicine
Department : General Medicine
Year : 2011
Abstract : Phosphodiesterases (PDEs) and their substrates, cAMP and cGMP, are ubiquitously expressed in the immune system. Inhibiting PDEs may represent a novel approach for regulating immune functions and have a therapeutic potential in the management of autoimmune diseases. Phosphodiesterase inhibitors (PDEi) have proved effective in clinical trials in the management of pulmonary artery hypertension and Raynaud's phenomenon. Data from animal models suggest that the immunomodulatory effect of PDEi may have a therapeutic potential in the management of diseases such as multiple sclerosis and rheumatoid arthritis. The antifibrotic potential of PDEi, as suggested by animal experiments, if proven in further studies will be a major step in the treatment of fibrosing diseases such as scleroderma and idiopathic pulmonary fibrosis. © 2011 Wiley Periodicals, Inc.
Cite this Research Publication : Pa Shenoy, Agarwal, Vb, Agarwal, Ab, Misra, Rb, and Naik, Sb, “Potential for phosphodiesterase inhibitors in the management of autoimmune diseases”, Drug Development Research, vol. 72, pp. 772-778, 2011.